The FDA highlights increased toxicity risks in patients with DPD deficiency when using Xeloda and 5-FU, urging genetic testing before treatment. DPD deficiency leads to severe side effects from ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
NuGenA (Nurse Led Genetic Counselling and Awareness): A proof-of-concept to implementation of genetic counseling for HBOC in LMICs. Clinical features and occurrence of other cancers in patients with ...
Fluorouracil is not recommended for use in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency. The Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback